Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 28, 2024, titled "Zydus and Dr. Reddy s announce licensing agreement for co-marketing of Pertuzumab biosimilar, a critical treatment for breast cancer patients in India".
Press Release Jun 28 2024
Filed with NSE · · 4 pages · English
Summary by 6ix AI
The product will be marketed under the brand names Sigrima by Zydus and Womab by Dr. Reddy’s. Zydus will receive upfront licensing income and milestone payments based on the achievement of specific targets.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jun 14 2024
- Press Release May 24 2024
- Press Release May 22 2024
- Press Release May 17 2024
- Press Release May 11 2024
Later from Zydus Lifesciences
- Press Release Jul 04 2024
- Press Release Jul 10 2024
- Press Release (Revised) Jul 10 2024
- Press Release Jul 17 2024
- Press Release Jul 19 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences